GEn1E Lifesciences: Using AI to Speed Up Trials for Immune-Modulating Drugs
A clinical-stage biotech uses its GRID AI platform to identify immune-modulating drug targets, pushing its lead compound GEn-1124 into Phase 2 clinical trials in just 2.5 years on a modest seed round.
Think & Rich